title: [Mood and cognitive disorders, and androgen deprivation].
abstract: Prostate cancer has become a chronic disease. In this context, it is important to take into account the quality of life of patients and their family in the therapeutic approach. Recent studies have demonstrated the importance of depression and the risk of suicide in patients with prostate cancer as well as the repercussions of the disease on the spouse and their relationship. The implication of hormonal treatment in the increase in risk of depression is difficult to affirm. Few studies have investigated this subject and they present methodological biases. Some authors report an increased risk of cognitive decline in patients on androgen deprivation. However, even if certain physiopathological hypotheses have been put forward, the imputability of the treatment on the alteration of cognitive functions has not been clearly established. Urologists are at the forefront of diagnosis and treatment of prostate cancer occurring most often in elderly subjects. Therefore, given the prevalence of depression syndromes and/or the alteration of cognitive functions in this population, the urologist must be aware of these different factors, which are potentially aggravated by the introduction of androgen deprivation. Based on a review of the recent literature, the authors suggest using a simple depression screening tool: confirmation of the diagnosis and management is within the competence of the general practitioner. As for the risk of cognitive decline, it seems difficult to imagine, and not necessarily relevant, to systematically propose a battery of neuropsychometric screening tests. On the other hand, giving the patient the G8 screening test can allow the urologist to assess whether the patient needs a geriatric consultation or not.
authors.affiliation: Service de Psychiatrie, CH Lagny - Marne La Vallée, 77400 Lagny sur Marne, France. fremontpmv@orange.fr
authors.forename: P
authors.initials: P
authors.lastname: Frémont
authors.forename: L
authors.initials: L
authors.lastname: Balardy
authors.forename: D
authors.initials: D
authors.lastname: Faramarzi-Roques
authors.forename: L
authors.initials: L
authors.lastname: Goldblatt
authors.forename: G
authors.initials: G
authors.lastname: Kouri
authors.forename: I
authors.initials: I
authors.lastname: Latorzeff
authors.forename: L
authors.initials: L
authors.lastname: Mourey
authors.forename: G
authors.initials: G
authors.lastname: Pasticier
authors.forename: F
authors.initials: F
authors.lastname: Vavdin
authors.forename: P
authors.initials: P
authors.lastname: Rischmann
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D003072:Cognition Disorders / Q000139:chemically induced*; D006801:Humans; D008297:Male; D019964:Mood Disorders / Q000139:chemically induced*; D011471:Prostatic Neoplasms / Q000188:drug therapy; D011795:Surveys and Questionnaires
chemical_list: D000726:Androgen Antagonists